quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 1, 2026

Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more

View original at seekingalpha.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more [February 2026 Yellow Desk Calendar Among Office Supplies] spawns/iStock via Getty Images Earnings season rolls into a high-impact week ahead, with results due from a broad cross-section of the market spanning Big…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Alphabet is a Buy with a $331 price target, pointing to accelerating Gemini AI adoption and expanding Google Cloud margins

    80% confidence
  • Amazon is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum, and improving DTC fundamentals

    80% confidence
  • Philip Morris reaffirmed its FY2025 profit guidance at Morgan Stanley Global Consumer & Retail Conference in December

    80% confidence
  • Disney is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum from franchises like Avatar and Zootopia 2, and improving DTC fundamentals driven by subscriber growth and expanding ARPUs

    80% confidence
  • Amazon remains a Strong Buy with a $319.56 price target and 32% upside, despite recent underperformance versus the S&P 500

    80% confidence
  • Pfizer remains firmly in the green zone into 2026, with the bullish case resting on oncology and vaccine pipeline alongside potentially best-in-class GLP-1/amylin candidates

    80% confidence
  • While PM now trades closer to fair value, further upside hinges on upgraded guidance, supporting a continued Buy stance

    80% confidence
  • Expectations are building for higher capital deployment (~$29B) and potentially ~44% growth in Google Cloud in early 2025

    80% confidence
  • Pfizer maintains a Sell rating citing persistent margin and growth headwinds

    80% confidence
  • Applying a conservative 16.5x EV/EBITDA multiple, AMZN still offers attractive upside, with margins and free cash flow expected to improve by 2026

    80% confidence
  • Philip Morris strong execution has driven a 108% total return since January 2024, more than double the S&P 500

    80% confidence
  • PFE trades at just ~8.5x forward non-GAAP earnings, well below peers such as AbbVie, Merck, and Eli Lilly, while offering a dividend yield north of 6%

    80% confidence
  • The rally has been driven primarily by robust ZYN growth, with nicotine pouch volumes up 36% Y/Y

    80% confidence
  • Valuation multiples sit at multi-decade highs, with EV/EBITDA near 26x and FCF yield compressed to ~1.8%

    80% confidence
  • Pfizer's 2026 guidance implies continued Y/Y declines, with revenue and EPS midpoints of $61B and $2.90, respectively

    80% confidence
  • Alphabet downgraded to Hold, noting that shares have nearly doubled in a year and appear fully priced

    80% confidence
  • Disney remains a Buy with strong FY26-FY27 EPS growth guidance and attractive valuations suggesting meaningful upside

    80% confidence

Data points we hold from this source

The Walt Disney Company · revenue25.60 billion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more — Source | Via News | pt.VIA.NEWS